Lung nodules occupy a peculiar and anxiety-inducing space in modern medicine: discovered incidentally on millions of chest scans each year, the vast majority are benign, yet a small fraction represent early-stage lung cancer — the malignancy most likely to be cured when caught at this stage. How clinicians navigate this uncertainty has enormous consequences for patient outcomes, from unnecessary invasive procedures to missed cancers.
This clinical practice review, published in the New England Journal of Medicine, synthesizes current evidence and guideline frameworks for evaluating pulmonary nodules — small, rounded opacities measuring less than three centimeters identified on CT imaging. The piece addresses risk stratification across nodule characteristics including size, morphology, density (solid versus subsolid), and growth rate, alongside patient-level factors such as smoking history and age. It incorporates assessment tools used to estimate malignancy probability and outlines surveillance intervals informed by major guidelines, while also touching on when procedural evaluation — including PET-CT or tissue sampling — becomes warranted.
From a broader clinical and public health perspective, this review arrives against a backdrop of rapidly expanding lung cancer screening programs using low-dose CT. As screening eligibility criteria have widened in recent years — particularly following updated U.S. Preventive Services Task Force recommendations — the volume of incidentally and intentionally discovered nodules is increasing substantially, making standardized, evidence-based evaluation protocols more critical than ever. The central challenge remains the risk-benefit calculus: over-investigation exposes patients to procedural harms and psychological burden, while under-investigation delays diagnosis of potentially curable early cancers. Key limitations of current risk models include their derivation from predominantly white, high-smoking-history cohorts, raising questions about generalizability. As a clinical synthesis rather than a novel trial, this review is best understood as a consolidation of existing knowledge rather than a paradigm shift — but its publication in NEJM signals its value as an authoritative reference for practicing clinicians managing this increasingly common diagnostic challenge.